AI assistant
HAEMONETICS CORP — Director's Dealing 2012
Oct 26, 2012
31565_dirs_2012-10-26_6e7209d5-f790-45bd-b6c1-057a4cfbd4af.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2012-10-24
Reporting Person: Helsel Dave (VP, Global Manufacturing)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-10-24 | Common Stock | A | 1536.0 | $0.0 | Acquired | 3312.0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-10-24 | Non-Qualified Stock Option (right to buy) | $78.11 | A | 14307.0 | Acquired | 2019-10-24 | Common Stock (14307.0) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) | $67.54 | 2019-04-10 | Common Stock (15954.0) | 15954.0 | Direct |
Footnotes
F1: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.
F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.